Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Income towards Parent Company (2016 - 2025)

Historic Income towards Parent Company for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Income towards Parent Company rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 14415.3%. This contributed to the annual value of -$64.0 million for FY2024, which is 1594.04% down from last year.
  • According to the latest figures from Q3 2025, Theravance Biopharma's Income towards Parent Company is $3.6 million, which was up 12846.91% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Income towards Parent Company ranged from a high of $927.1 million in Q3 2022 and a low of -$23.1 million during Q4 2024
  • Over the past 5 years, Theravance Biopharma's median Income towards Parent Company value was $3.6 million (recorded in 2025), while the average stood at $50.3 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 440000.49% in 2022, then plummeted by 31854.13% in 2023.
  • Over the past 5 years, Theravance Biopharma's Income towards Parent Company (Quarter) stood at $25.8 million in 2021, then plummeted by 84.9% to $3.9 million in 2022, then plummeted by 318.54% to -$8.5 million in 2023, then crashed by 171.45% to -$23.1 million in 2024, then surged by 115.65% to $3.6 million in 2025.
  • Its Income towards Parent Company stands at $3.6 million for Q3 2025, versus $54.8 million for Q2 2025 and -$13.5 million for Q1 2025.